πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Anlotinib and Sintilimab injection

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  2. Anlotinib+ Liposomal Doxorubicin

    The First People's Hospital of Lianyungang

    Sarcoma

    phase 2 small molecule active

    1 trial

  3. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

  4. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial

  5. Apatinib

    The First People's Hospital of Lianyungang

    Thyroid

    phase 2 small molecule active

    1 trial

  6. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Apatinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Apatinib

    The First People's Hospital of Lianyungang

    Malignant Ascites

    phase 2 small molecule active

    1 trial

  9. Apatinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Apatinib

    The First People's Hospital of Lianyungang

    Intrahepatic Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  11. Apatinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Esophageal Squamous Carcinoma

    phase 2 small molecule active

    1 trial

  13. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. Apatinib Combined With SHR-1210 Injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  15. Apatinib mesylate tablets

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  16. Apatinib+ SHR-1210（CamrelizumabοΌ‰

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  17. Apheresis and Bridging Therapy

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 other completed

    1 trial

  18. Ara-C Group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. Arm 1： Standard Synchronous Group

    The First People's Hospital of Lianyungang

    Advanced Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. Arm A

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  21. Atorvastatin

    The First People's Hospital of Lianyungang

    Myocardial Infarction

    phase 2 small molecule active

    1 trial

  22. Aumolertinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. Azacitidine

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome

    phase 2 small molecule completed

    1 trial

  25. Azacitidine (AZA) with Ruxolitinib

    The First People's Hospital of Lianyungang

    MDS/MPN

    phase 2 small molecule active

    1 trial

  26. Azacitidine Injection

    The First People's Hospital of Lianyungang

    B Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  27. Azacitidine in Combination With Venetoclax

    The First People's Hospital of Lianyungang

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  28. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  29. BM-MSCs

    The First People's Hospital of Lianyungang

    Kidney Transplantation

    phase 2 other active

    2 trials

  30. Baritinib

    The First People's Hospital of Lianyungang

    Intracerebral Hemorrhage

    phase 2 small molecule completed

    1 trial

  31. Becotatug Vedotin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  32. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  33. Bevacizumab

    The First People's Hospital of Lianyungang

    Malignant Pleural Effusion

    phase 2 small molecule active

    1 trial

  34. Bevacizumab

    The First People's Hospital of Lianyungang

    Lung, Carcinoma

    phase 2 small molecule active

    1 trial

  35. Bevacizumab Biosimilar IBI305

    The First People's Hospital of Lianyungang

    Post-orthotopic Liver Transplantation

    phase 2 small molecule active

    1 trial

  36. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  37. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  38. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  39. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  40. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  41. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  42. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  43. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  44. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  45. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  46. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  47. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  48. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.